A Review of the Properties of Spiradoline: A Potent and Selective k‐Opioid Receptor Agonist (original) (raw)

ABSTRACT

The selective k‐opioid receptor agonist spiradoline mesylate (U62,066E), an arylacetamide, was synthesized with the intention of creating an analgesic that, while still retaining its analgesic properties, would be devoid of the, mainly μ receptor mediated, side effects such as physical dependence and respiratory depression associated with morphine. Spiradoline is highly selective for the k receptor with K i of 8.6 nM in guinea pig. Examination of the enantiomers of spiradoline, showed the (–)enantiomer to be responsible for the k agonist properties. Spiradoline easily penetrates the blood brain barrier, and does not seem to have any significant active metabolites. In preclinical studies, spiradoline has a short duration of action with a peak at around 30 min after administration.

The analgesic properties of spiradoline are well documented in mice and rats. Antitussive properties have also been reported in rats. Furthermore, spiradoline was reported to display effects suggestive of neuroprotective properties in animal models of ischemia. In humans, spiradoline is a potent diuretic. It also produces significant sedation presumably due to its antihistamine properties. Preclinical studies have shown that spiradoline reduces blood pressure and heart rate, and has possible antiarrhythmic properties. Clinical studies did not confirm these findings.

k Receptors inhibit dopaminergic neurotransmission. Spiradoline, given systematically to rats, produces a significant and long lasting decrease in dopamine release, and in loco‐motor activity. It has also antipsycho tic‐like effect in animal behavioral tests. At low doses spiradoline was reported to decrease tics in patients with Tourette's syndrome. Although spiradoline had promising effects in animal tests of analgesia, and a reasonably good safety profile in preliminary studies, it did not replace morphine as an analgesic. The available clinical data suggest that spiradoline produces disturbing adverse effects such as diuresis, sedation, and dysphoria at doses lower than those needed for analgesic effects. Thus, future development of spiradoline‐like analgesic compounds should preferably focus on reduction of unwanted effects on the central nervous system.

Spiradoline, which currently is commercially available for preclinical research, might prove useful in some psychiatric conditions and possibly as a neuroprotective agent.

Keywords: Analgesics; Antitussives; Dopamine receptors; Dopamine‐opioid interaction; k‐Opioid agonists; Neuroprotection; Opioids; Spiradoline; U62,066E; U50488H

Full Text

The Full Text of this article is available as a PDF (97.9 KB).

References

• 1.Althaus JS, DiFazio C, Moscicki JC, VonVoigtlander PF. Enhancement of anesthetic effect of halothane by spiradoline, a selective κ‐agonist. Anesth Analg 1988;67:823–827. [PubMed] [Google Scholar]
• 2.Borkowski KR. Studies on the adrenomedullary dependence of κ‐opioid agonist‐induced diuresis in conscious rats. Br J Pharmacol 1989;98:1151–1156. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 3.Boyle TJ, Masuda T, Cunningham T. Effects of a agonist, spiradoline mesylate (U62,066E), on activation and vaginocervical stimulation produced analgesia in rats. Brain Res Bull 2001;54:213–218. [DOI] [PubMed] [Google Scholar]
• 4.Briggs SL, Rech RH, Sawyer DC. κ Antinociceptive activity of spiradoline in the cold‐water tail‐flick assay in rats. Pharmacol Biochem Behav 1998;60:467–472. [DOI] [PubMed] [Google Scholar]
• 5.Butelman ER, Harris TJ, Kreek MJ. Effects of E‐2078, a stable dynorphin A(1–8) analog, on sedation and serum prolactin levels in rhesus monkeys. Psychopharmacology 1999;147:73–80. [DOI] [PubMed] [Google Scholar]
• 6.Chappell PB, Leckman JF, Scahill LD, Hardin MT, Anderson G, Cohen DJ. Neuroendocrine and behavioral effects of the selective κ agonist spiradoline in Tourette's syndrome: A pilot study. Psychiat Res 1993;47:267–280. [DOI] [PubMed] [Google Scholar]
• 7.Cheng C‐Y, Wu S‐C, Hsin L‐W, Tam SW. Selective reversible and irreversible ligands for the κ‐opioid receptor. J Med Chem 1992;35:2243–2247. [DOI] [PubMed] [Google Scholar]
• 8.Cook CD, Barrett AC, Syvanthong C, Picker MJ. Modulatory effects of dopamine D3/2 agonists on opioid‐induced antinociception and diuresis in the rat. Psychopharmacology 2000;152:14–23. [DOI] [PubMed] [Google Scholar]
• 9.Cutler D. κ‐Opioid receptor patented. TIPS 2001;22:62. [Google Scholar]
• 10.Di Chiara G, Imperato A. Opposite effects of μ and κ opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 1988;244:1067–1080. [PubMed] [Google Scholar]
• 11.Donzanti BA, Althaus JS, Payson MM, Von Voigtlander PF. κ Agonist‐induced reduction in dopamine release: Site of action and tolerance. Res Comm Chem Pathol Pharmacol 1992;78:193–210. [PubMed] [Google Scholar]
• 12.Engber TM, Boldry RC, Chase TN. The κ‐opioid receptor agonist spiradoline differentially alters the rotational response to dopamine D1 and D2 agonists. Eur J Pharmacol 1991;200:171–173. [DOI] [PubMed] [Google Scholar]
• 13.Gerfen CR, Engber TM, Mahan LC, _et al._D1 and D2 dopamine receptor‐regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429–1432. [DOI] [PubMed] [Google Scholar]
• 14.Glick SD, Maisonneuve IM, Raucci J, Archer S. κ Opioid inhibition of morphine and cocaine self‐administration in rats. Brain Res 1995;681:147–152. [DOI] [PubMed] [Google Scholar]
• 15.Giardina G, Clarke GD, Dondio G, Petrone G, Sbacchi M, Vecchietti V. Selective κ‐opioid agonists: Synthesis and structure‐activity relationships of piperidines incorporating an oxocontaining acyl group. J Med Chem 1994;37:3482–3491. [DOI] [PubMed] [Google Scholar]
• 16.Giuffra M, Mouradian MM, Davis TL, Ownby J, Chase TN. Dynorphin agonist therapy of Parkinson's disease. Clin Neuropharmacol 1993;16:444–447. [DOI] [PubMed] [Google Scholar]
• 17.Gulat‐Marnay C, Lafitte A, Arrang J‐M, Schwartz J‐C. Modulation of histamine release in the rat brain by κ‐opioid receptors. J Neurochem 1990;55:47–53. [DOI] [PubMed] [Google Scholar]
• 18.Hall ED, Wolf DL, McCall RB. Cardiovascular effects of the κ‐opioid receptor agonists U50488H and spiradoline mesylate. Circ Shock 1988;26:409–417. [PubMed] [Google Scholar]
• 19.Hall ED, Pazara KE. Quantitative analysis of effects of κ‐opioid agonists on postischemic hippocampal CA1 neuronal necrosis in gerbils. Stroke 1988;19:1008–1012. [DOI] [PubMed] [Google Scholar]
• 20.Harasawa Y, Kimura M, Hayashi S. Inhibitory effect of spiradoline, a k opioid receptor agonist, on Ca2+ induced contraction and the intracellular Ca2+ concentration in porcine coronary artery. Cardiovasc Res 1991;25:802–806. [DOI] [PubMed] [Google Scholar]
• 21.Holtzman SG. Further characterization of the discriminative stimulus effects of spiradoline. Pharmacol Biochem Behav 2000;66:517–522. [DOI] [PubMed] [Google Scholar]
• 22.Holtzman SG, Cook L, Steinfels GF. Discriminative effects of spiradoline, a κ‐opioid agonist. Psychopharmacology 1991;105:447–452. [DOI] [PubMed] [Google Scholar]
• 23.Holtzman SG, Steinfels GF. Monoamine systems in the discriminative effects of spiradoline, a κ‐opioid agonist. Pharmacol Biochem Behav 1994;47:575–578. [DOI] [PubMed] [Google Scholar]
• 24.Horan P, de Costa BR, Rice KC, Porreca F. Differential antagonism of U69,593‐ and bremazocine‐induced antinociception by (–)‐UPHIT: Evidence of κ‐opioid receptor multiplicity in mice. J Pharmacol Exp Ther 1991;257:1154–1161. [PubMed] [Google Scholar]
• 25.Horan P, Porreca F. Lack of cross‐tolerance between U69,593 and bremazocine suggests κ‐opioid receptor multiplicity in mice. Eur J Pharmacol 1993;239:93–98. [DOI] [PubMed] [Google Scholar]
• 26.Kamei J, Tanihara H, Kasuya Y. Antitussive effects of two specific κ‐opioid agonists, U‐50,488H and U‐62,066E in rats. Eur J Pharmacol 1990;187:281–286. [DOI] [PubMed] [Google Scholar]
• 27.Kamei J, Tanihara H, Kasuya Y. The abilities of specific κ‐opioid agonists, U‐50,488H and U‐62,066E, to cause antitussive tolerance were lower than that of morphine. Jpn J Pharmacol 1991;56:557–561. [DOI] [PubMed] [Google Scholar]
• 28.Kamei J, Tanihara H, Kasuya Y. Modulation of κ‐mediated activity in rats by a δ‐agonist. Res Commun Chem Pathol Pharmacol 1992;76:375–378. [PubMed] [Google Scholar]
• 29.Kanarek RB, Homoleski A, Wiatr C. Intake of palatable sucrose solution modifies the actions of spiradoline, a κ‐opioid receptor agonist, on analgesia and feeding behavior in male and female rats. Pharmacol Biochem Behav 2000;65:97–104. [DOI] [PubMed] [Google Scholar]
• 30.Kosterlitz HW, Paterson SJ, Robson LE. Characterization of the κ‐subtype of the opiate receptor in the guinea‐pig brain. Br J Pharmacol 1981;73:939–949. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 31.Kosterlitz HW, Paterson SJ. Types of opioid receptors: Relation to antinociception. Philos Trans R Soc Lond B Biol Sci 1985;308:291–297. [DOI] [PubMed] [Google Scholar]
• 32.Kunihara M, Ohyama M, Nakano M, Hayashi S. Analgesic activity of spiradoline mesylate (U‐62,066E), a κ opioid agonist in mice. Life Sci 1989;45:1191–1198. [DOI] [PubMed] [Google Scholar]
• 33.Kunihara M, Ohyama M, Nakano M. Central monoaminergic mechanisms in mice and analgesic activity of spiradoline mesylate, a selective κ‐opioid receptor agonist. Eur J Pharmacol 1992;214:111–118. [DOI] [PubMed] [Google Scholar]
• 34.Kunihara M, Ohyama M, Nakano M. Effects of spiradoline mesylate, a selective κ‐opioid receptor agonist, on the central dopamine system with relation to mouse locomotor activity and analgesia. Jpn J Pharmacol 1993;62:223–230. [DOI] [PubMed] [Google Scholar]
• 35.Lahti RA, Mickelson MM, Jodelis KS, McCall JM. Comparative neuroanatomical distribution of the κ and μ opioid receptors in guinea pig brain sections. Eur J Pharmacol 1989;166:563–566. [DOI] [PubMed] [Google Scholar]
• 36.Lishmanov YB, Maslov LN, Ugdyzhekova DS. Participation of central and peripheral κ1 and κ2 opioid receptors in arrhythmogenesis. Clin Exp Pharmacol Physiol 1999;26:716–723. [DOI] [PubMed] [Google Scholar]
• 37.Lishmanov YB, Maslov LN, Naryzhnaya NV, Tam SW. Ligands for opioid and sigma receptors improve cardiac electrical stability in rats models of post‐infarction cardiosclerosis and stress. Life Sci 1999;65:PL13–7. [DOI] [PubMed] [Google Scholar]
• 38.Marin C, Engber TM, Chaudhuri P, Peppe A, Chase TN. Effects of κ‐receptor agonists on D1 and D2 dopamine agonist and antagonist‐induced behaviors. Psychopharmacology 1996;213:215–221. [DOI] [PubMed] [Google Scholar]
• 39.Meecham KG, Boyle SJ, Hunter JC, Hughes J. An in vitro profile for the (+) and (‐) enantiomers of spiradoline and PD11702. Eur J Pharmacol 1989;173:151–157. [DOI] [PubMed] [Google Scholar]
• 40.Mello NK, Negus SS. Interactions between κ opioid agonists and cocaine: Preclinical studies. Ann NY Acad Sci 2000;909:104–132. [DOI] [PubMed] [Google Scholar]
• 41.Ohno M, Yamamoto T, Ueki S. Analgesic and discriminative stimulus properties of U‐62,066E, the selective κ‐opioid agonist, in the rat. Psychopharmacology 1992;106:31–38. [DOI] [PubMed] [Google Scholar]
• 42.Pearl SM, Glick SD. Prolonged antagonism of morphine‐induced locomotor stimulation by κ opioid agonists: Enhancement by prior morphine. Neurosci Lett 1996;213:5–8. [DOI] [PubMed] [Google Scholar]
• 43.Peters GR, Ward NJ, Antal EG, Lai PY, DeMaar EW. Diuretic actions in man of a selective κ opioid agonist: U‐62,066E. J Pharmacol Exp Ther 1987;240:128–131. [PubMed] [Google Scholar]
• 44.Piercey MF, Einspahr FJ. Spinal analgesic actions of κ‐receptor agonists, U‐50488H and spiradoline (U‐62066). J Pharmacol Exp Ther 1989;251:267–271. [PubMed] [Google Scholar]
• 45.Piercey MF, Varner K Schroeder LA. Analgesic activity of intraspinally administered dynorphin and ethylketocyclazocine. Eur J Pharmacol 1982;80:283–284. [DOI] [PubMed] [Google Scholar]
• 46.Pitts RC, Dykstra LA. Antinociceptive and response rate‐altering effects of κ opioid agonists spiradoline, enadoline and U69 593 alone, and in combination with opioid antagonists in squirrel monkeys. J Pharmacol Exp Ther 1994;271:1501–1508. [PubMed] [Google Scholar]
• 47.Pugsley MK, Penz WP, Walker MJA, Wong TM. Cardiovascular actions of the k‐agonist, U50,488H, in the absence and presence of opioid receptor blockade. Br J Pharmacol 1992;105:521–526. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 48.Pugsley MK, Penz WP, Walker MJA. Cardiovascular actions of U50,488H and related κ agonists. Cardiovasc Drug Rev 1993;11:151–164. [Google Scholar]
• 49.Pugsley MK, Saint DA, Hayes ES, Kramer D, Walker MJA. Sodium channel‐blocking properties of spiradoline, a κ‐receptor agonist, are responsible for its antiarrhythmic action in the rat. J Cardiovasc Pharmacol 1998;32:863–874. [DOI] [PubMed] [Google Scholar]
• 50.Pugsley MK, Yu EJ, Goldin AL. Spiradoline, a κ‐opioid receptor agonist, produces tonic‐ and use‐dependent block of sodium channels expressed in Xenopus oocytes. Gen Pharmacol 2000;34:417–427. [DOI] [PubMed] [Google Scholar]
• 51.Rimoy GH, Bhaskar NK, Wright DM, Rubin PC. Mechanism of diuretic action of spiradoline (U‐62066E) — a κ‐opioid receptor agonist in the human. Br J Clin Pharmacol 1991;32:611–615. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 52.Rimoy GH, Wright DM, Bhaskar NK, Rubin PC. The cardiovascular and central nervous effects in the human of U‐62066E. A selective opioid receptor agonist. Eur J Clin Pharmacol 1994;46:203–207. [DOI] [PubMed] [Google Scholar]
• 53.Robson LE, Gillan MGC, Kosterlitz HW. Species differencies in the concentrations and distributions of opioid binding sites. Eur J Pharmacol 1985;112:65–71. [DOI] [PubMed] [Google Scholar]
• 54.Shen S, Ingenito AJ. Depressor effect of κ opioid agonist on hypertension induced by isolation in the rat. Clin Exp Hypertens 1999;21:275–297. [DOI] [PubMed] [Google Scholar]
• 55.Shen S, Ingenito AJ. Comparison of cardiovascular responses to intrahippocampal μ, δ and κ agonists in spontaneously hypertensive rats and isolation‐induced hypertensive rats. J Hypertens 1999;17:497–505. [DOI] [PubMed] [Google Scholar]
• 56.Shibata S, Tominaga K, Watanabe S. κ‐Opioid receptor agonist protects against ischemic reduction of 2‐deoxy glucose uptake in morphine‐tolerant rats. Eur J Pharmacol 1995;279:197–202. [DOI] [PubMed] [Google Scholar]
• 57.Slitzgi GR, Ludens JH. Displacement of 3H‐EKC binding by opioids in rat kidney: A correlate to diuretic activity. Life Sci 1985;36:2189–2193. [DOI] [PubMed] [Google Scholar]
• 58.Smith MA, Picker MJ. Examination of the κ agonist and antagonist properties of opioids in the rat drug discrimination procedure: Influence of training dose and intrinsic efficacy. Behav Pharmacol 1995;6:703–717. [PubMed] [Google Scholar]
• 59.Stachura Z, Herman ZS. The influence of the κ agonist spiradoline (U62066E) on the analgesic activity of some opioids at the spinal level. Pol J Pharmacol 1994;46:37–41. [PubMed] [Google Scholar]
• 60.Szmuszkovicz J, Von Voigtlander PF. Benzeneacetamide amines: Structurally novel non‐μ opioids. J Med Chem 1982;25:1125–1126. [DOI] [PubMed] [Google Scholar]
• 61.Ur E, Wright DM, Bouloux PM, Grossman A. The effects of spiradoline (U‐62066E), a κ‐opioid receptor agonist, on neuroendocrine function in man. Br J Pharmacol 1997;120:781–784. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 62.Yamada K, Imai M, Yoshida S. Mechanism of diuretic action of U‐62,066E, a κ opioid agonist. Eur J Pharmacol 1989;160:229–237. [DOI] [PubMed] [Google Scholar]
• 63.Yamada K, Nakano M, Yoshida S. Inhibition of elevated arginine vasopressin secretion in response to osmotic stimulation and acute haemorrhage by U‐62066E, a κ‐opioid receptor agonist. Br J Pharmacol 1990;99:384–388. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 64.Von Voigtlander PF, Lahti RA, Ludens JH. U‐50488: A selective and structurally novel non‐μ (±) opioid agonist. J Pharmacol Exp Ther 1983;224:7–12. [PubMed] [Google Scholar]
• 65.Von Voigtlander PF, Lewis RA. Analgesic and mechanistic evaluation of spiradoline, a potent κ opioid. J Pharmacol Exp Ther 1988;246:259–262. [PubMed] [Google Scholar]
• 66.Wadenberg M‐L, Madaj B, Pais A. Antipsychotic‐like profile, without catalepsy, of the selective κ‐opioid receptor agonist spiradoline in rats. Abstr Soc Neurosci 2001;27. [Google Scholar]
• 67.Wright RC, Ingenito AJ. Prevention of isolation‐induced hypertension by intrahippocampal administration of a nonpeptide κ‐opioid receptor agonist. Hippocampus 2001;11:445–451. [DOI] [PubMed] [Google Scholar]
• 68.Zaratin P, Clarke GD. Comparative effects of selective κ‐opioid receptor agonists on dopamine levels in the dorsal caudate of freely moving rats. Eur J Pharmacol 1994;264:151–156. [DOI] [PubMed] [Google Scholar]
• 69.Zhai QZ, Ingenito AJ. Sustained antihypertensive effects of chronic administration of two κ‐opioid agonists in spontaneously hypertensive rats. Am J Ther 1997;4:173–180. [DOI] [PubMed] [Google Scholar]